These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11010718)

  • 1. Pharmaceutical marketplace dynamics.
    Strongin RJ
    Issue Brief Natl Health Policy Forum; 2000 May; (755):1-15. PubMed ID: 11010718
    [No Abstract]   [Full Text] [Related]  

  • 2. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS
    Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicine and the pharmaceutical industry: what's right, what's wrong, and what's to come.
    Tan SY
    Singapore Med J; 1998 Mar; 39(3):91-5. PubMed ID: 9632964
    [No Abstract]   [Full Text] [Related]  

  • 4. How to Reduce Prescription Drug Prices: First, Do No Harm.
    Atlas S
    Mo Med; 2020; 117(1):14-15. PubMed ID: 32158034
    [No Abstract]   [Full Text] [Related]  

  • 5. Lowering the cost of prescription drugs.
    Jindal B
    J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
    [No Abstract]   [Full Text] [Related]  

  • 6. India's pharmaceutical industry: hype or high tech take-off?
    Malhotra P; Lofgren H
    Aust Health Rev; 2004 Nov; 28(2):182-93. PubMed ID: 15527398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription drug trend begins showing modest slowdown.
    Capitation Rates Data; 2002 Jul; 7(7):76-80. PubMed ID: 12164063
    [No Abstract]   [Full Text] [Related]  

  • 8. Prescription drug pushers. Patents and ads are the big reasons pills are priced like perfume and caviar.
    Sherrid P
    US News World Rep; 2000 Oct; 129(17):40-2. PubMed ID: 11184929
    [No Abstract]   [Full Text] [Related]  

  • 9. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 10. Perspectives. CMS and Wall Street report...
    Med Health; 2003 Jan; 57(4):7-8. PubMed ID: 12602066
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of generic market entry on antibiotic prescriptions in the United States.
    Kållberg C; Hudson J; Salvesen Blix H; Årdal C; Klein E; Lindbæk M; Outterson K; Røttingen JA; Laxminarayan R
    Nat Commun; 2021 May; 12(1):2937. PubMed ID: 34006862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
    Cheng N; Banerjee T; Qian J; Hansen RA
    J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 14. A Legal Test for the Pharmaceutical Company Practice of "Product Hopping".
    Klusty T
    AMA J Ethics; 2015 Aug; 17(8):760-2. PubMed ID: 26270876
    [No Abstract]   [Full Text] [Related]  

  • 15. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 16. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protect pharmaceutical innovation.
    Musselwhite LW; Andrews J
    Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
    [No Abstract]   [Full Text] [Related]  

  • 19. Perspectives. Drug formularies pose legal threat to providers.
    Moskowitz DB
    Faulkner Grays Med Health; 1995 Feb; 49(6):suppl 1-4. PubMed ID: 10139750
    [No Abstract]   [Full Text] [Related]  

  • 20. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.